Mitotaan

  • Kerkhofs TM, Ettaieb MH, Hermsen IG, Haak HR. Developing treatment for adrenocortical carcinoma.
    Endocr Relat Cancer. 2015 Dec;22(6)
  • Kerkhofs TM, Derijks LJ, Ettaieb H, den Hartigh J, Neef K, Gelderblom H, Guchelaar HJ, Haak HR. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
    Ther Drug Monit. 2015 Feb;37(1):58-65
  • Kerkhofs TM, Derijks LJ, Ettaieb MH, Eekhoff EM, Neef C, Gelderblom H, den Hartigh J, Guchelaar HJ, Haak HR. Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring.
    Eur J Endocrinol. 2014 Dec;171(6):677-83
  • Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, Skogseid B, Leboulleux S, Mantero F, Haak HR, Fassnacht M.
    Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
    J Clin Endocrinol Metab. 2013 Dec;98(12):4759-67
  • De Francia S et al. Mitotane treatment for adrenocortical carcinoma: an overview.
    Minerva Endocrinol 2012 Mar;37(1):9-23
  • Hermsen IGC et al. Plasma concentrations of o,p’DDD, o,p’DDA, and o,p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
    JCEM 2011 Jun;96(6):1844-51
  • Hermsen IG, den Hartigh J, Haak HR. Mitotane serum level analysis; good agreement between two different assays.
    Clin Endocrinol (Oxf). 2010 Aug;73(2):271-2
  • Veytsman I et al. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
    J Clin Oncol 2009 Sep 20;27(27):4619-29
  • Hermsen IG, Gelderblom H, Kievit J, Romijn JA, Haak HR.
    Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.Eur J Endocrinol. 2008 Jun;158(6):911-9.
  • Haak HR et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.
    Br J Cancer 1994 May;69(5):947-51

Mitotaan als adjuvante behandeling: 

  • Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F, Perotti P, Feelders RA, deVries, JH, Zaggia B, De Francia S, Volante M, Haak HR, Allolio B, Al Ghuzlan A, Fassnacht M, Berruti A. Mitotane levels predict the outcome of patients with adrenal carcinoma treated adjuvantly following radical resection.
    Eur J Endocrinol. 2013 Jul 29;169(3):263-70
  • Berruti A et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
    J Clin Oncol 2010 Aug 10;28(23):e401-2
  • Terzolo M et al. Adjuvant mitotane treatment for adrenocortical carcinoma.
    NEJM 2007 Jun 7;356(23):2372-80
  • van Ditzhuijsen CI, van de Weijer R, Haak HR. Adrenocortical carcinoma.
    Neth J Med. 2007 Feb;65(2):55-60.